A pesar de la importancia pronóstica de alcanzar los objetivos terapéuticos en los valores de colesterol, la mayoría de los pacientes hipercolesterolémicos no los alcanzan. Esto es debido en parte a la progresiva pérdida de eficacia de las estatinas en dosis elevadas. La ezetimiba es un inhibidor selectivo de la absorción del colesterol que ha demostrado su eficacia y buena tolerancia clínica en varios estudios en los que se ha utilizado en asociación con diversas estatinas. Con ello, permite alcanzar los objetivos terapéuticos deseables en un mayor número de pacientes.
Palabras clave
Hipercolesterolemia
Fármacos
Ezetimiba
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
P.R. Hebert, J.M. Gaziano, K.S. Chan, C.H. Hennekens.
Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.
JAMA, (1997), 278 pp. 313-321
[2.]
J.C. LaRosa, J. He, S. Vupputuri.
Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.
JAMA, (1999), 282 pp. 2340-2346
[3.]
Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation. 2002;106:3143-421.
[4.]
S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr, L.T. Clark, D.B. Hunninghake, National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association, et al.
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Circulation, (2004), 110 pp. 227-239
[5.]
EUROASPIRE II Study Group.
Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.
Eur Heart J, (2001), 22 pp. 554-572
[6.]
L. Rodríguez Padial, C. Maicas Bellido, J. Alcalá López, M. Velázquez Martín, B. Gil Polo.
Escasa aplicación de las medidas de prevención en los pacientes con diabetes mellitus tipo 2 y enfermedad arterial coronaria en España. Estudio DIETRIC.
Rev Clin Esp, (2005), 205 pp. 14-18
[7.]
R.H. Knopp.
Drug treatment of lipid disorders.
N Engl J Med, (1999), 341 pp. 498-511
[8.]
A.S. Wierzbicki, D.P. Mikhailidis, R. Wray, M. Schacter, R. Cramb, W.G. Simpson, et al.
Statin-fibrate combination: therapy for hyperlipidemia: a review.
Curr Med Res Opin, (2003), 19 pp. 155-168
[9.]
M. Van Heek, C.F. France, D.S. Compton, R.L. McLeod, N.P. Yumibe, K.B. Alton, et al.
In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461.
J Pharmacol Exp Ther, (1997), 283 pp. 157-163
[10.]
J.M. Pascual Izuel, E. Rodilla Sala, C. Sánchez Juan.
Eficacia clínica de la ezetimiba y uso combinado con estatinas.
Rev Clin Esp, (2005), 205 pp. 496-498
[11.]
T. Sudhop, D. Lutjohann, A. Kodal, M. Igel, D.L. Tribble, S. Shah, et al.
Inhibition of intestinal cholesterol absorption by ezetimibe in humans.
Circulation, (2002), 106 pp. 1943-1948
[12.]
T. Kosoglou, I. Meyer, E.P. Veltri, P. Statkevich, B. Yang, Y. Zhu, et al.
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin.
Br J Clin Pharmacol, (2002), 54 pp. 309-319
[13.]
T. Kosoglou, P. Statkevich, B. Yang, R. Suresh, Y. Zhu, T. Boutros, et al.
Pharmacodynamic interaction between ezetimibe and rosuvastatin.
Curr Med Res Opin, (2004), 20 pp. 1185-1195
[14.]
T. Kosoglou, P. Statkevich, A.O. Johnson-Levonas, J.F. Paolini, A.J. Bergman, K.B. Alton.
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.
Clin Pharmacokinet, (2005), 44 pp. 467-494
[15.]
D.P. Mikhailidis, A.S. Wierzbicki, S.S. Daskalopoulou, N. Al-Saady, H. Griffiths, G. Hamilton.
The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel.
Curr Med Res Opin, (2005), 21 pp. 959-969
[16.]
A.S. Brown, R.G. Bakker-Arkema, L. Yellen, R.W. Henley Jr, R. Guthrie, C.F. Campbell, et al.
Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
J Am Coll Cardiol, (1998), 32 pp. 665-672
[17.]
J.A. Velasco, J. Cosín, M. de Oya, E. De Teresa.
Programa de intervención para mejorar la prevención secundaria del infarto de miocardio. Resultados del estudio PRESENTE (PREvención SEcuNdaria TEmprana).
Rev Esp Cardiol, (2004), 57 pp. 146-154
[18.]
C. Gagne, H.E. Bays, S.R. Weiss, P. Mata, K. Quinto, M. Melino, et al.
Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
Am J Cardiol, (2002), 90 pp. 1084-1091
[19.]
C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, et al.
Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
N Engl J Med, (2004), 350 pp. 1495-1504
[20.]
J. Ferrieres, J. Lambert, S. Lussier-Cacan, J. Davignon.
Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation.
Circulation, (1995), 92 pp. 290-295
[21.]
P. Jones, S. Kafonek, I. Laurora, D. Hunninghake.
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Am J Cardiol, (1998), 81 pp. 582-587
[22.]
P.H. Jones, M.H. Davidson, E.A. Stein, H.E. Bays, J.M. McKenney, E. Miller, et al.
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Am J Cardiol, (2003), 92 pp. 152-160
[23.]
D.I. Chasman, D. Posada, L. Subrahmanyan, N.R. Cook, V.P. Stanton Jr, P.M. Ridker.
Pharmacogenetic study of statin therapy and cholesterol reduction.
JAMA, (2004), 291 pp. 2821-2827
[24.]
E.A. Stein.
Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor.
Eur Heart J, (2001), 3 pp. E11-E16
[25.]
P.D. Thompson, P. Clarkson, R.H. Karas.
Statin-associated myopathy.
JAMA, (2003), 289 pp. 1681-1690
[26.]
H.R. Davis Jr, K.K. Pula, K.B. Alton, R.E. Burrier, R.W. Watkins.
The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Metabolism, (2001), 50 pp. 1234-1241
[27.]
M.H. Davidson, T. McGarry, R. Bettis, L. Melani, L.J. Lipka, A.P. LeBeaut, et al.
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.
J Am Coll Cardiol, (2002), 40 pp. 2125-2134
[28.]
C.M. Ballantyne, J. Houri, A. Notarbartolo, L. Melani, L.J. Lipka, R. Suresh, Ezetimibe Study Group, et al.
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
Circulation, (2003), 107 pp. 2409-2415
[29.]
B. Kerzner, J. Corbelli, S. Sharp, L.J. Lipka, L. Melani, A. LeBeaut, Ezetimibe Study Group, et al.
Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.
Am J Cardiol, (2003), 91 pp. 418-424
[30.]
L. Melani, R. Mills, D. Hassman, R. Lipetz, L. Lipka, A. LeBeaut, Ezetimibe Study Group, et al.
Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
Eur Heart J, (2003), 24 pp. 717-728
[31.]
A.C. Goldberg, A. Sapre, J. Liu, R. Capece, Y.B. Mitchel, Ezetimibe Study Group.
Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.
Mayo Clin Proc, (2004), 79 pp. 620-629
[32.]
L. Masana, P. Mata, C. Gagne, W. Sirah, M. Cho, A.O. Johnson-Levonas, Ezetimibe Study Group, et al.
Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
Clin Ther, (2005), 27 pp. 174-184
[33.]
C.M. Ballantyne, M.A. Blazing, T.R. King, W.E. Brady, J. Palmisano.
Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.
Am J Cardiol, (2004), 93 pp. 1487-1494
[34.]
C.M. Ballantyne, L.J. Lipka, P.T. Sager, J. Strony, J. Alizadeh, R. Suresh, et al.
Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia.
Int J Clin Pract, (2004), 58 pp. 653-658
[35.]
L. Reyderman, T. Kosoglou, D.L. Cutler, S. Maxwell, P. Statkevich.
The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe.
Curr Med Res Opin, (2005), 21 pp. 1171-1179
[36.]
C.M. Ballantyne, N. Abate, Z. Yuan, T.R. King, J. Palmisano.
Dosecomparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
Am Heart J, (2005), 149 pp. 464-473
[37.]
R.P. Giugliano, E. Braunwald.
The Year in NonST-Segment Elevation Acute Coronary Syndromes.
J Am Coll Cardiol, (2005), 46 pp. 906-919
[38.]
C.A. Dujovne, M.P. Ettinger, J.F. McNeer, L.J. Lipka, A.P. LeBeaut, R. Suresh, Ezetimibe Study Group, et al.
Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia.
Am J Cardiol, (2002), 90 pp. 1092-1097
[39.]
T. Feldman, M. Koren, W. Insull Jr, J. McKenney, H. Schrott, A. Lewin, et al.
Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals.
Am J Cardiol, (2004), 93 pp. 1481-1486
[40.]
L. Simons, M. Tonkon, L. Masana, D. Maccubbin, A. Shah, M. Lee, et al.
Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.
Curr Med Res Opin, (2004), 20 pp. 1437-1445
[41.]
L.M. Gaudiani, A. Lewin, L. Meneghini, I. Perevozskaya, D. Plotkin, Y. Mitchel, et al.
Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients.
Diabetes Obes Metab, (2005), 7 pp. 88-97
[42.]
C. Brohet, S. Banai, A.M. Alings, R. Massaad, M.J. Davies, C. Allen.
LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia.
Curr Med Res Opin, (2005), 21 pp. 571-578
[43.]
T.A. Pearson, M.A. Denke, P.E. McBride, W.P. Battisti, W.E. Brady, J. Palmisano.
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe addon to statin for effectiveness (EASE) trial.
Mayo Clin Proc, (2005), 80 pp. 587-595
[44.]
J. Jurado, R. Seip, P.D. Thompson.
Effectiveness of ezetimibe in clinical practice.
Am J Cardiol, (2004), 93 pp. 641-643
[45.]
A.M. Xydakis, J.R. Guyton, P. Chiou, J.L. Stein, P.H. Jones, C.M. Ballantyne.
Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia.
Am J Cardiol, (2004), 94 pp. 795-797
[46.]
M. Farnier, M.W. Freeman, G. Macdonell, I. Perevozskaya, M.J. Davies, Y.B. Mitchel, The Ezetimibe Study Group, et al.
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
Eur Heart J, (2005), 25 pp. 897-905
[47.]
P.T. Sager, L. Melani, L. Lipka, J. Strony, B. Yang, R. Suresh, Ezetimibe Study Group, et al.
Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein.
Am J Cardiol, (2003), 92 pp. 1414-1418
[48.]
A.S. Wierzbicki, E. Doherty, P.J. Lumb, G. Chik, M.A. Crook.
Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias.
Curr Med Res Opin, (2005), 21 pp. 333-338
[49.]
R.A. Hegele, J. Guy, M.R. Ban, J. Wang.
NPC1L1 haplotype associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe.
Lipids Health Dis, (2005), 4 pp. 16
[50.]
P.E. Ziajka, M. Reis, S. Kreul, H. King.
Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe.
Am J Cardiol, (2004), 93 pp. 779-780
[51.]
R.H. Knopp, H. Gitter, T. Truitt, H. Bays, C.V. Manion, L.J. Lipka, et al.
Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.
Eur Heart J, (2003), 24 pp. 729-741
[52.]
Association of Ezetrol (ezetimibe) with myalgia, rhabdomyolysis, hepatitis, pancreatitis and thrombocytopenia. Public Advisory Health Canada and Merck Frosst/Schering Pharmaceuticals. Disponible en: www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/ezetrol_hpc_e.html
[53.]
C. Van Heyningen.
Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe.
Ann Clin Biochem, (2005), 42 pp. 402-404
[54.]
Fundación Instituto Catalán de Farmacología. Ezetimiba: efectos adversos musculares y hepáticos. Butlletí CROC 2005;18(2):7. Disponible en: www.icf.uab.es/informacion/boletines/bg/bf182.05.pdf
[55.]
Medicines Control Agency [homepage on internet]. Adverse drugs reactions online information tracking. Ezetimibe. Disponible en: www.mhra.gov/uk/home/idcplg?IdcService=SS_GET_PAGE&nodeId=5
Copyright ©
2006. Sociedad Española de Cardiología